The U.S. Food and Drug Administration has given tentative approval for a generic version of the AIDS drug Viread.
The approval means that generic tablets of tenofovir disoproxil fumarate can be considered for purchase under the President's Emergency Plan for AIDS Relief (PEPFAR), a five-year, $15 billion effort to fight the HIV/AIDS pandemic, the FDA said Wednesday.
"The fight to save lives with high-quality anti-retroviral treatment is of significant importance to FDA," Gary Buehler, director of FDA's Office of Generic Drugs, said in a release. "Our scientists have been working diligently to make safe and effective treatments for AIDS available as quickly as possible to combat this worldwide problem."
The tenofovir disoproxil fumarate 300 milligram tablets are manufactured by Matrix Laboratories, LTD, of Andhra Pradesh, India.
The FDA said PEPFAR has helped provide anti-retroviral treatment for a total of more than 1.3 million men, women and children in 15 focus countries in sub-Saharan Africa, Asia and the Caribbean.
Copyright 2007 by United Press International
Related stories:
UCSF study will test new vaginal microbicide for herpes and HIV
A team of researchers at UCSF is seeking young women to participate in the first US study of the safety of a new a vaginal gel designed to prevent herpes and HIV infection. If it is effective and approved by the U.S. Food and Drug Administration, the gel would be an important weapon in the fight against HIV because it would allow women to protect themselves from infection rather than relying on their partners to use condoms.
Generic pediatric AIDS Drug gets U.S. OK
The U.S. Food and Drug Administration has tentatively approved the generic version of Abacavir Sulfate Oral Solution for use by pediatric AIDS victims.
HIV drug maraviroc effective for drug-resistant patients
As many as one quarter of HIV patients have drug resistance, limiting their treatment options and raising their risk for AIDS and death. Now, maraviroc, the first of a new class of HIV drugs called CCR5 receptor antagonists, has been shown to be effective over 48 weeks for drug-resistant patients with R5 HIV-1, a variation of the virus found in more than half of HIV-infected patients.
Researchers evaluate cost-effectiveness of genetic screening to guide initial HIV treatment
A major study from a team of researchers from Weill Cornell Medical College and Massachusetts General Hospital has found that a recent change to HIV-treatment guidelines recommending genetic screening is cost-effective under certain conditions. The new recommendation suggests conducting a genetic screening test prior to prescribing the drug abacavir, one of the preferred first-line drugs for the treatment for HIV-infected adults.
Potential diabetes treatment selectively kills autoimmune cells from human patients
In experiments using blood cells from human patients with diabetes and other autoimmune disorders, Massachusetts General Hospital (MGH) researchers have confirmed the mechanism behind a potential new therapy for type 1 diabetes. A team led by Denise Faustman, MD, PhD, director of the MGH Immunobiology Laboratory, showed that blocking a metabolic pathway regulating the immune system specifically eliminated immune cells that react against a patient's own tissues.
Report says dietary supplements for horses, dogs and cats need better regulation
The growing use of animal dietary supplements has raised several concerns, including the safety of specific supplements and the approaches taken to determine their safeness. A new National Research Council report, requested by the Center for Veterinary Medicine of the U.S. Food and Drug Administration, assesses whether the addition of three dietary supplements -- lutein, evening primrose oil, and garlic -- to the diets of horses, dogs, or cats may cause significant adverse health effects.
Personalized immunotherapy to fight HIV/AIDS
For a long time, the main obstacle to creating an AIDS vaccine has been the high genetic variability of the HIV virus. Dr. Jean-Pierre Routy and his team from the Research Institute of the McGill University Health Centre (MUHC), in collaboration with Dr. Rafick Sékaly from the Université de Montréal, have overcome this difficulty by designing a personalized immunotherapy for HIV-infected patients. The team's findings were presented on August 5 at the XVII International AIDS Conference in Mexico City.
Trapping white blood cells proves novel strategy against chronic viral infections
Seeing disease-fighting white blood cells vanish from the blood usually signals a weakened immune system. But preventing white blood cells' circulation by trapping them in the lymph nodes can help mice get rid of a chronic viral infection, researchers at Yerkes National Primate Research Center and the Emory Vaccine Center have found.